PVS-10200

Biologic

Takeda

PVS-10200 is one of 31 biologic programs targeting Peripheral Artery Disease. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Peripheral Artery DiseaseActive, not recruiting

Peripheral Artery DiseasePhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

42 competitors in Peripheral Artery Disease

#DrugCompanyPhaseTrials

Victoza

Novo Nordisk

Approved

1 2

Benicar

Novartis

Approved

1 3

Kuvan

BioMarin Pharmaceutical

Approved

1 4

Xarelto

WWim Janssens

Approved

4 5

Glucophage

EMD Serono

Approved

2 6

Zocor

OOrganon and Co

Approved

1 7

Brilinta

AstraZeneca

Phase 3

4 8

Acetylsalicylic Acid

Bayer

Approved

1 9

Bayer Aspirin

Bayer

Phase 3

3 10

Colcrys

Alnylam Pharmaceuticals

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Peripheral Artery Disease1 trial

Study of PVS-10200 for the Treatment of Restenosis in Patients With Peripheral Artery Disease (TRIUMPH)

Completed· Takeda logo

Takeda·Phase 1/2·NCT01099215·21 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for PVS-10200. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PVS-10200 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PVS-10200. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Company: Takeda

PVS-10200

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Peripheral Artery Disease1 trial

References

Drug Info

Quick Facts

Related News